Human Disease Model Report: HPV-related carcinoma, E5-E6-E7-UBE3A models

General Information

Name

HPV-related carcinoma, E5-E6-E7-UBE3A models

FlyBase ID

FBhh0001073

Disease Ontology Term

carcinoma

Parent Disease

OMIM

Overview

A Drosophila model of HPV-related carcinoma has been developed using the papillomavirus E6 gene HPV18\E6 plus the human ubiquitin ligase gene Hsap\UBE3A expressed in the eye or wing disc. Co-expression of HPV18\E6 and Hsap\UBE3A results in visible phenotypes in disc-derived tissues not observed for expression of either gene alone; however, phenotypes indicative of cellular transformation or tumorigenesis are not observed. When, in addition, activated Ras85D or activated Notch N is expressed, tumorigenic phenotypes and evidence of metastatic cell migration are observed. This model has been extended using the papillomavirus E5, E6, and E7 genes HPV16\E5, HPV16\E6, and HPV16\E7 genes, in which all three genes are co-expressed in the eye disc with Hsap\UBE3A.

Using the eye phenotype, this system has been used to identify the signaling pathways involved in E6 + UBE3A phenotypes; a dominant negative form of the insulin receptor InR exacerbates the phenotype, implicating insulin signaling in this process. Effects upon Drosophila orthologs of known targets of E6 in human cells have been assessed; of the genes tested, the most significant effect was upon the molecular scaffolding protein Dmel\Magi (orthologous to human MAGI1, MAGI2, and MAGI3). A genetic screen identified Dmel\IKKβ as a modifier of the eye phenotype; this interaction is conserved in human cells.

UBE3A acts in the ubiquitin proteasome pathway and as a transcriptional coactivator. There is a single orthologous gene in Drosophila, Dmel\Ube3a, for which classical amorphic alleles, RNAi targeting constructs, and alleles caused by insertional mutagenesis have been generated. In analogous experiments, HPV18\E6 co-expressed with the fly Dmel\Ube3a gene in discs fails to produce visible phenotypes, and thus has not been used in this model.

The constitutively active Ras85D mutation, Ras85D^V12, is analogous to oncogenic mutations found in human RAS proteins. Variant(s) implicated in human disease tested (as analogous mutation in fly gene): G12V in the fly Ras85D gene (corresponds to G12V in the human KRAS and HRAS genes). See also the human disease model report 'cancer, multiple, RAS-related' (FBhh0000474). Much of the work in flies investigating the role of the Notch pathway in development of cancer has involved combining Notch signaling dysregulation with another cancer model. This is typically achieved by using targeted expression of an activated form of Notch (N); see also the human disease model report 'cancer, multiple, Notch signaling pathway' (FBhh0000766).

[updated Jan. 2023 by FlyBase; FBrf0222196]

Disease Summary Information

Disease Summary: HPV-related carcinoma, E5-E6-E7-UBE3A models

OMIM report

Human gene(s) implicated

Symptoms and phenotype

HPV is thought to be responsible for more than 90% of anal and cervical cancers, about 70% of vaginal and vulvar cancers, and 60% of penile cancers. Cancers of the oropharynx (back of the throat, including the base of the tongue and tonsils) traditionally have been associated with use of tobacco and alcohol, but recent studies show that about 60% to 70% of cancers of the oropharynx may be linked to HPV (https://www.cdc.gov/cancer/hpv/basic_info/cancers.htm).

(FlyBase Curators, 2013-)

Human papillomaviruses (HPVs) are the etiological agents in nearly all cases (99.7%) of cervical cancer, and the HPV E6 protein is one of two viral oncoproteins that is expressed in virtually all HPV-positive cancers. HPV16 and HPV18 are the high-risk types most frequently associated with cervical squamous cell carcinomas (50% and 20%, respectively). The HPV E6 and E7 proteins are the only two viral genes expressed in virtually all HPV-positive cervical carcinomas (Beaudenon and Huibregtse, 2008; pubmed:19007434).

(FlyBase Curators, 2013-)

Genetics

E7 is the major transforming oncoprotein of HPV. It promotes increased cell proliferation by dysregulating the G1/S transition, and delays cell differentiation. E6 and E7 can each immortalize cells, but appear to act cooperatively in tumor formation, with E7 being involved in the early stages and E6 accelerating progression to malignancy. A third HPV protein, E5, expressed early in the HPV life cycle, provides support for viral infection and transformation of cells. E5 enhances the oncogenic abilities of E6 and E7 in cellular transformation and tumor formation. (Hashemi, et al., 2022, pubmed:36508448; FBrf0255248 and references cited therein).

(FlyBase Curators, 2013-)

Cellular phenotype and pathology

Molecular information

High-risk HPV E6 proteins bind directly to the cellular ubiquitin ligase E6AP/UBE3A, causing its substrate specificity to be altered so that it stably associates with and polyubiquitylates TP53, resulting in degradation of TP53 (Beaudenon and Huibregtse, 2008; pubmed:19007434).

(FlyBase Curators, 2013-)

Multiple functions of E6, including interaction with UBE3A, TP53 and PDZ domain-containing substrates, appear to be required for its ability to bring about cell transformation and to contribute towards malignancy in animal models (Beaudenon and Huibregtse, 2008, pubmed:19007434; FBrf0233222 and references cited therein).

(FlyBase Curators, 2013-)

External links

Gene2Function (human gene): UBE3A
Gene Cards: UBE3A
MedlinePlus (gene): UBE3A
KEGG Disease Pathways: Pathways in Cancer
MARRVEL (human gene): UBE3A
NCBI (Entrez) gene: UBE3A; ubiquitin protein ligase E3A

Disease synonyms

HPV 18 E6 model

HPV-related carcinoma, E6-UBE3A models

human papillomavirus-related carcinoma

Search term: HPV-related cervical cancer

Search term: HPV-related cervical carcinoma

Related Diseases

Related human health report(s)

infection by viral pathogens

Ortholog Information

Human gene(s) in FlyBase

Hsap\UBE3A

Human gene (HGNC)

Symbol / Name

UBE3A; ubiquitin protein ligase E3A

D. melanogaster ortholog (based on DIOPT)

Dmel\Ube3a

(DIOPT, 2013-)

Comments on ortholog(s)

One to one: 1 human to 1 Drosophila

Other mammalian ortholog(s) used

D. melanogaster Gene Information (2)

Dmel\Ras85D

Gene Snapshot

Ras oncogene at 85D (Ras85D) encodes a protein that acts downstream of several cell signals, most notably from Receptor Tyrosine Kinases, to regulate tissue growth and development. When abnormally activated it can direct developmental defects and tissue hyperplasia, mimicking aspects of human disease including Rasopathies and cancer, respectively. [Date last reviewed: 2019-03-14]

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

High-scoring ortholog of human genes KRAS, HRAS, and NRAS (many to many; multiple paralogs and orthologs in both species). Dmel\Ras85D shares 78-86% identity and 86-92% similarity with KRAS, HRAS, and NRAS; for these three human genes, Ras85D is the highest-scoring ortholog in Drosophila.

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Dmel\N

Gene Snapshot

Contributions welcome

Molecular function (GO)

Cellular component (GO)

Gene Groups / Pathways

Comments on ortholog(s)

Moderate- to high-scoring ortholog of human NOTCH1, NOTCH2, NOTCH3, NOTCH4 (1 Drosophila to 4 human). Dmel\N shares 43-44% identity and 56-57% similarity with NOTCH1 and NOTCH2.

Orthologs and Alignments from DRSC

DIOPT - DRSC Integrative Ortholog Prediction Tool - Click the link below to search for orthologs in Humans

H. sapiens (Human)

Other Genes Used: Viral, Bacterial, Synthetic (2)

Summary of Physical Interactions (87 groups)

Ras85D

protein-protein

Interacting group

Assay

References

Ras85D - alt

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - Arc1

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - ave

pull down, anti tag western blot

(Maisonneuve et al., 2024)

Ras85D - CG31550

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - cindr

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - cno

two hybrid, anti tag coimmunoprecipitation, autoradiography

(Boettner and Van Aelst, 2007, Carmena et al., 2006)

Ras85D - Droj2

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - eIF3i

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - glo

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - Gyc76C

anti tag coimmunoprecipitation, anti tag western blot

(Iwashita et al., 2020)

Ras85D - lark

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - mod(mdg4)

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - Nf1

gtpase assay, autoradiography

(Walker et al., 2006)

Ras85D - Nop60B

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - Pi3K92E

pull down, western blot, two hybrid

(Orme et al., 2006)

Ras85D - pico

two hybrid

(Lyulcheva et al., 2008)

Ras85D - Pyk

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - Raf

anti tag coimmunoprecipitation, anti tag western blot, two hybrid, pull down

(Yang and Terman, 2012, Ding et al., 2010, Mishra et al., 2005)

Ras85D - rau

pull down, anti tag western blot

(Sieglitz et al., 2013)

Ras85D - Rgl

two hybrid

(Mirey et al., 2003)

Ras85D - RpL6

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpL15

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpL21

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpL23A

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpL24

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpS2

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - RpS27

anti tag coimmunoprecipitation, peptide massfingerprinting

(Friedman et al., 2011)

Ras85D - spri

anti tag coimmunoprecipitation, anti tag western blot

(Jekely et al., 2005)

Ras85D - Sumo

pull down, covalent binding, western blot, anti tag coimmunoprecipitation, Identification by mass spectrometry

(Nie et al., 2009)

protein-protein

Interacting group

Assay

References

two hybrid, enzyme linked immunosorbent assay, electron microscopy, molecular weight

(Kelly et al., 2010, Pei and Baker, 2008, Fortini and Artavanis-Tsakonas, 1994)

N - Abl

anti bait coimmunoprecipitation, western blot

(Koca et al., 2022)

N - Akap200

anti tag coimmunoprecipitation, western blot, anti tag western blot

(Bala Tannan et al., 2018)

N - arm

anti bait coimmunoprecipitation, western blot

(Koca et al., 2022, Hayward et al., 2005)

N - Atg8a

proximity ligation assay, fluorescence microscopy

(Katz et al., 2025)

N - baz

anti tag coimmunoprecipitation, anti tag western blot

(Wu et al., 2024)

N - Caf1-55

anti tag coimmunoprecipitation, anti tag western blot

(Yu et al., 2013)

N - Caf1-105

anti tag coimmunoprecipitation, anti tag western blot

(Yu et al., 2013)

N - Caf1-180

anti tag coimmunoprecipitation, anti tag western blot

(Yu et al., 2013)

N - Cdk8

pull down, western blot

(Park et al., 2003)

N - CG10916

experimental knowledge based

(Guruharsha et al., 2011)

N - Chi

anti tag coimmunoprecipitation, western blot, pull down

(Sachan et al., 2015)

N - cno

anti tag coimmunoprecipitation, western blot, autoradiography, anti bait coimmunoprecipitation, two hybrid

(Pérez-Gómez et al., 2013, Carmena et al., 2006)

N - crb

proximity ligation assay, fluorescence microscopy

(Nemetschke and Knust, 2016)

N - D

affinity technology, tag visualisation by alkaline phosphatase activity

(Pérez et al., 2005)

N - Dab

pull down, autoradiography, western blot, anti bait coimmunoprecipitation, anti tag coimmunoprecipitation

(Kannan et al., 2018, Le Gall et al., 2008, Le Gall and Giniger, 2004, Giniger, 1998)

N - Delta

affinity technology, inferred by author, bead aggregation assay, fluorescence microscopy, enzyme linked immunosorbent assay, anti bait coimmunoprecipitation, western blot, tag visualisation, phenotype-based detection assay, cross-linking study, pull down, tag visualisation by alkaline phosphatase activity, atomic force microscopy

(Pandey et al., 2019, Yamamoto et al., 2012, Acar et al., 2008, Pei and Baker, 2008, Xu et al., 2007, Parks et al., 2006, Ahimou et al., 2004, Bruckner et al., 2000, Wesley and Saez, 2000, Wesley, 1999, Rebay et al., 1991, Fehon et al., 1990)

N - dsh

pull down, western blot, autoradiography, anti bait coimmunoprecipitation, two hybrid

(Capilla et al., 2012, Muñoz-Descalzo et al., 2010, Hayward et al., 2005, Ramain et al., 2001, Axelrod et al., 1996)

N - dx

anti tag coimmunoprecipitation, western blot, nuclear magnetic resonance, two hybrid, cosedimentation in solution, predetermined participant, anti tag western blot

(Carter et al., 2023, Shimizu et al., 2014, Muñoz-Descalzo et al., 2010, Matsuno et al., 1995, Diederich et al., 1994)

N - Eip75B

anti tag coimmunoprecipitation, western blot, proximity ligation assay, fluorescence microscopy

(Wang et al., 2024)

N - Eogt

enzymatic study

(Sakaidani et al., 2011)

N - htk

anti tag coimmunoprecipitation, western blot, anti bait coimmunoprecipitation, two hybrid, anti tag western blot

(Singh et al., 2019)

N - Kap-α3

two hybrid, pull down, western blot, anti tag coimmunoprecipitation

(Sachan et al., 2013)

N - kuz

protease assay, western blot, inferred by author

(Pan and Rubin, 1997)

N - lilli

anti tag coimmunoprecipitation, anti tag western blot

(Liu et al., 2017)

N - mam

three hybrid, protein three hybrid, anti tag coimmunoprecipitation, peptide massfingerprinting

(Gahr et al., 2019, Nagel et al., 2017, Yuan et al., 2016, Maier et al., 2011, Veraksa et al., 2005, Petcherski and Kimble, 2000)

N - mask

anti bait coimmunoprecipitation, western blot, two hybrid

(Sarkar et al., 2025)

N - MED17

pull down, western blot

(Park et al., 2003)

N - MED21

pull down, western blot

(Park et al., 2003)

N - MED31

pull down, western blot

(Park et al., 2003)

N - msn

coimmunoprecipitation, western blot

(Mishra et al., 2015)

N - ND-30

anti tag coimmunoprecipitation, western blot

(Lee et al., 2013)

N - Nedd4

pull down, western blot, anti tag coimmunoprecipitation

(Sakata et al., 2004)

N - numb

two hybrid, pull down, autoradiography

(Guo et al., 1996)

N - Ofut1

anti tag coimmunoprecipitation, western blot, anti tag western blot

(Sasamura et al., 2007, Okajima et al., 2005)

N - Pink1

anti tag coimmunoprecipitation, western blot

(Lee et al., 2013)

N - Pngl

experimental knowledge based

(Guruharsha et al., 2011)

N - polo

experimental knowledge based

(Guruharsha et al., 2011)

N - pyd

anti tag coimmunoprecipitation, anti tag western blot

(Shimizu et al., 2017)

N - Rbfox1

anti bait coimmunoprecipitation, western blot

(Shukla et al., 2017)

N - sca

anti tag coimmunoprecipitation, western blot

(Petruccelli et al., 2018)

N - Ser

inferred by author, anti bait coimmunoprecipitation, cross-linking study, western blot, pull down, tag visualisation by alkaline phosphatase activity, affinity technology, fluorescence microscopy, confocal microscopy, bead aggregation assay, tag visualisation, anti tag coimmunoprecipitation

(Pandey et al., 2019, Fleming et al., 2013, Pérez-Gómez et al., 2013, Yamamoto et al., 2012, Kim et al., 2010, Xu et al., 2007, Pérez et al., 2005, Wesley, 1999, Rebay et al., 1991)

N - shg

anti bait coimmunoprecipitation, western blot

(Sasaki et al., 2007)

N - spdo

anti bait coimmunoprecipitation, western blot, anti tag coimmunoprecipitation, anti tag western blot, pull down

(Upadhyay et al., 2013, O'Connor-Giles and Skeath, 2003)

N - Su(dx)

pull down, molecular weight estimation by staining, isothermal titration calorimetry, predetermined participant, autoradiography, nuclear magnetic resonance, western blot

(Yao et al., 2018, Jennings et al., 2007, Wilkin et al., 2004)

N - Su(H)

protein three hybrid, isothermal titration calorimetry, predetermined participant, two hybrid, pull down, autoradiography, anti tag coimmunoprecipitation, peptide massfingerprinting, anti bait coimmunoprecipitation, western blot, cosedimentation, molecular sieving, molecular weight estimation by staining, anti tag western blot, electrophoretic mobility shift assay, electrophoretic mobility supershift assay, coimmunoprecipitation, electron microscopy, three hybrid

N - Taf9

anti tag coimmunoprecipitation, anti tag western blot

(Xie et al., 2014)

N - Traf6

two hybrid, anti tag coimmunoprecipitation, western blot, pull down

(Mishra et al., 2014)

N - trio

anti bait coimmunoprecipitation, western blot

(Kannan et al., 2018, Le Gall et al., 2008)

N - uif

anti tag coimmunoprecipitation, anti tag western blot

(Loubéry et al., 2014)

N - Vps26

anti tag coimmunoprecipitation, anti tag western blot

(Li et al., 2018)

N - Vps35

anti tag coimmunoprecipitation, anti tag western blot

(Li et al., 2018)

N - wg

anti bait coimmunoprecipitation, cross-linking study, western blot

(Wesley, 1999)

N - wry

inferred by author, confocal microscopy, bead aggregation assay

(Kim et al., 2010)

N - yki

proximity ligation assay, fluorescence microscopy

(Wang et al., 2024)

N - zip

anti bait coimmunoprecipitation, western blot, Identification by mass spectrometry, anti tag western blot

(Verma et al., 2024)

RNA-protein

Interacting group

Assay

References

N - Sxl

nucleic acid uv cross-linking assay, autoradiography, anti bait coimmunoprecipitation, quantitative reverse transcription pcr

(Penn and Schedl, 2007)

N - TBPH

pull down, quantitative reverse transcription pcr

(Swain et al., 2016)

Alleles Reported to Model Human Disease (Disease Ontology) (56 alleles)

Ras85D

Models Based on Experimental Evidence ( 17 )

Allele

Disease

Evidence

References

Ras85D^HMS01294

model of Noonan syndrome 3

CEA

(Cattaneo et al., 2020)

Ras85D^G12V.UAS

model of cancer

CEA with RhoGEF2^RE.UAS

(Khoo et al., 2013)

CEA with Rok^CAT.UAS

(Khoo et al., 2013)

CEA with sqh^{E20E21.UAS.cCa}

(Khoo et al., 2013)

Ras85D^G13Q.UAS

model of cancer

CEA

(Xu et al., 2023)

CEA with Pten^HMS00044, Rbf^HMS03004

(Parkhitko et al., 2021)

Ras85D^N17.UAS

model of Noonan syndrome 3

CEA

(Cattaneo et al., 2020)

Ras85D^Q13.UAS

model of cancer

CEA

(Tamamouna et al., 2021)

Ras85D^V12.GMR

model of cancer

CEA

(Okada et al., 2023)

Ras85D^V12.S35.UAS

model of cardiomyopathy

CEA

(Yu et al., 2013)

model of carcinoma

CEC

(Karim and Rubin, 1998)

Ras85D^V12.UAS

model of carcinoma

CEA

(Martínez-Abarca Millán and Martín-Bermudo, 2023, Ito and Igaki, 2021, Kong et al., 2021, Rackley et al., 2021, Soler Beatty et al., 2021, Wei et al., 2021, Wu et al., 2021, Murcia et al., 2019, Zoranovic et al., 2018, Pérez et al., 2015, Igaki et al., 2006)

CEA with dlg1^GD4689

(Santabárbara-Ruiz and Léopold, 2021)

CEA with scrib⁶⁷³

(Amcheslavsky et al., 2018, Pérez et al., 2015)

CEC

(Rosen et al., 2019, Karim and Rubin, 1998)

CEC with scrib¹

(Rosen et al., 2019)

CEA with l(2)gl⁴

(Ding et al., 2022, Singh et al., 2022, Ito and Igaki, 2021, Wu et al., 2021, Mishra-Gorur et al., 2019, Zhang et al., 2019, Srivastava et al., 2007, Igaki et al., 2006)

CEA with Lkb1^4A4-2

(Rackley et al., 2021)

CEA with scrib¹

(Kong et al., 2021, Mishra-Gorur et al., 2019, Srivastava et al., 2007, Igaki et al., 2006, Uhlirova and Bohmann, 2006)

CEA with dlg1¹⁴

(Ito and Igaki, 2021, Igaki et al., 2006)

CEA with shg^k03401

(Igaki et al., 2006)

CEA with msn³²⁰⁸

(Kong et al., 2021)

CEA with sna^UAS.cAa

(Wu et al., 2021)

CEA with scrib^KK101128

(Murcia et al., 2019)

CEA with scrib^HMJ21977

(Snigdha et al., 2021)

CEA with Csk^Q156Stop

(Hirabayashi and Cagan, 2015)

CEA with Csk^Q156Stop, InR^A1325D.UAS

(Hirabayashi and Cagan, 2015)

model of cancer

CEA with fmt¹

(Ma et al., 2017)

CEA with PpV^Δ1

(Ma et al., 2017)

CEA with l(2)gl⁴

(Guo et al., 2020, Ma et al., 2017, Ma et al., 2013, Pagliarini and Xu, 2003)

CEA with PpV^GD7532

(Ma et al., 2017)

CEA

(Khalili et al., 2023, Martínez-Abarca Millán et al., 2023, Enomoto et al., 2021, Santabárbara-Ruiz and Léopold, 2021, Tamamouna et al., 2021, Ma et al., 2020, Jung et al., 2019, Rives-Quinto et al., 2017, Chabu and Xu, 2014, Hirabayashi et al., 2013, Ma et al., 2013)

CEA with scrib⁶⁷³

(Katheder et al., 2017, Pérez et al., 2017)

CEA with scrib¹

(Kakemura and Igaki, 2024, Cong et al., 2021, Hodgson et al., 2021, Katheder et al., 2017, Figueroa-Clarevega and Bilder, 2015, Külshammer et al., 2015, Stickel and Su, 2014, Willoughby et al., 2013, Wu et al., 2010, Pagliarini and Xu, 2003)

CEA with dlg1^GD4689

(Katheder et al., 2017, Muzzopappa et al., 2017, Figueroa-Clarevega and Bilder, 2015, Willecke et al., 2011)

CEA with scrib^j7B3

(Waghmare et al., 2024, Pagliarini and Xu, 2003)

CEA with Src64B^UAS.cCa

(Enomoto et al., 2021)

CEA with dlg1¹⁴

(Kakemura and Igaki, 2024, Pagliarini and Xu, 2003)

CEA with baz⁴

(Pagliarini and Xu, 2003)

CEA with sdt^XN

(Pagliarini and Xu, 2003)

CEA with Cdc42¹

(Pagliarini and Xu, 2003)

CEA with dor^C107

(Chi et al., 2010)

CEA with dor⁸

(Chi et al., 2010)

CEA with dor^D185

(Chi et al., 2010)

CEA with car^RNAi.UAS

(Chi et al., 2010)

CEA with Vps16A^RNAi.UAS.WIZ

(Chi et al., 2010)

CEA with upd1^UAS.cUa

(Wu et al., 2010)

CEA with upd2^UAS.cUa

(Wu et al., 2010)

CEA with upd1^UAS.cUa, upd2^UAS.cUa, upd3^UAS.cUa

(Wu et al., 2010)

CEA with l(2)gl^unspecified

(Xu et al., 2023, Wu et al., 2010)

CEA with pnut^GD1512

(Gerlach et al., 2018)

CEC with l(2)gl⁴

(Ma et al., 2014)

CEA with Hsap\S100A4^wt.UAS

(Ismail et al., 2017)

CEA with scrib^RNAi.UAS.cUa

(Hodgson et al., 2021)

CEA with Csk^Q156Stop

(Hirabayashi et al., 2013)

CEA with scrib^KK101128

(Muzzopappa et al., 2017)

CEA with mud^JF02911

(Muzzopappa et al., 2017)

CEA with mud^HMS01458

(Muzzopappa et al., 2017)

CEA with N^RNAi.P.UAS

(Tamamouna et al., 2021)

CEA with N^DN.UAS.cUa

(Xu et al., 2023)

CEA with emei^GD3587

(Ma et al., 2020)

CEA with Rox8^GD11645

(Guo et al., 2020)

CEA with BacA\p35^UAS.cHa

(Khalili et al., 2023)

CEA with dlg1^RNAi.UAS.cUa

(Bakopoulos et al., 2023)

model of intestinal cancer

CEA

(Cabrera et al., 2023, Nászai et al., 2021)

CEA with Apc2^N175K, Apc^Q8

(Martorell et al., 2014, Martorell et al., 2014)

model of colorectal cancer

CEA

(Bangi et al., 2012)

model of leukemia

CEA

(Arefin et al., 2017)

CEA with l(2)gl^KK100777

(Arefin et al., 2017)

CEA with scrib^KK101128

(Arefin et al., 2017)

model of benign neoplasm

CEA with Alg9^c02021

(de Vreede et al., 2018)

DOES NOT model cancer

CEA with Hsap\S100A4^Δ2.UAS

(Ismail et al., 2017)

model of heart disease

CEA

(Karekar et al., 2021)

model of prostate cancer

CEA

(Rambur et al., 2020)

model of high grade glioma

CEA

(Kumar et al., 2024)

CEA with Pten^RNAi.UAS.cUa

(Cheng et al., 2016)

model of kidney cancer

CEA

(Zeng et al., 2010)

model of ovarian carcinoma

CEA with aPKC^ΔN.UAS

(Hsi et al., 2023)

model of hypertrophic cardiomyopathy

CEA

(Petersen et al., 2022)

Ras85D^V12.ey

model of carcinoma

CEC

(Karim and Rubin, 1998)

Ras85D^V12.cUa.UAS

model of cervical cancer

CEA

(Padash Barmchi et al., 2016)

CEA with Hsap\UBE3A^UAS.cRa, HPV18\E6^UAS.Tag:MYC

(Padash Barmchi et al., 2016)

CEA with Hsap\UBE3A^UAS.cRa, HPV18\E6^{V158A.UAS.Tag:MYC}

(Padash Barmchi et al., 2016)

model of cancer

CEA with l(2)gl⁴

(Fangninou et al., 2023, Liu et al., 2022, Yang et al., 2022)

CEA with Ptp61F^Δ

(Liu et al., 2022)

CEA with Syx7³¹¹⁹

(Liu et al., 2022)

CEA with Rabex-5³⁶⁷²

(Liu et al., 2022)

CEA with Vps36²⁵⁸⁶

(Liu et al., 2022)

CEA with TSG101^P26

(Liu et al., 2022)

CEA with N^DN.UAS.cUa

(Lee et al., 2021)

CEA with dlg1^RNAi.UAS.cUa

(Lodge et al., 2021)

CEA

(Yang et al., 2022, Dong et al., 2021, Yeom et al., 2021, Dunn et al., 2018, Vicente et al., 2018)

CEA with scrib¹

(Yang et al., 2022, Khezri et al., 2021)

CEA with baz⁴

(Yang et al., 2022)

CEA with fmt¹

(Yang et al., 2022)

CEA with dlg1^GD4689

(Yang et al., 2022)

CEA with Ptip³⁸⁰⁴

(Dong et al., 2021)

model of colorectal cancer

CEA

(Zipper et al., 2022)

CEA with Pten^sgRNA.UAS

(Zipper et al., 2022)

CEA with Med^sgRNA.UAS

(Zipper et al., 2022)

CEA with cic^sgRNA.UAS

(Zipper et al., 2022)

CEA with Apc2^sgRNA.UAS

(Zipper et al., 2022)

CEA with Apc^sgRNA.UAS

(Zipper et al., 2022)

CEA with p53^sgRNA.UAS

(Zipper et al., 2022)

CEA with p53^RNAi.UAS.cUa, Pten^GD13500, Apc^RNAi.UAS.cUa, Med^RNAi.UAS.cUa

(Bangi et al., 2016)

CEA with p53^RNAi.UAS.cUa, Pten^GD13500, Apc^RNAi.UAS.cUa

(Bangi et al., 2016)

CEA with p53^RNAi.UAS.cUa, Apc^RNAi.UAS.cUa, Med^RNAi.UAS.cUa

(Bangi et al., 2016)

CEA with Pten^GD13500, Apc^RNAi.UAS.cUa, Med^RNAi.UAS.cUa

(Bangi et al., 2016)

model of cardiomyopathy

CEA

(Yu et al., 2013)

model of adenocarcinoma

CEA with l(2)gl^GD4047

(Casas-Tintó et al., 2016)

CEA with l(2)gl^GD4047, wupA^JF02172

(Casas-Tintó et al., 2016)

model of carcinoma

CEA

(Guo et al., 2024, Hogan et al., 2009)

CEA with l(2)gl⁴

(Sun et al., 2019)

CEA with dlg1^HMS00172

(Toggweiler et al., 2016)

model of intestinal cancer

CEA with Apc^Q8

(Campbell et al., 2019)

CEA

(Kim et al., 2022, Dai et al., 2020, Singh et al., 2016)

CEA with Apc2^N175K, Apc^Q8

(Parisi et al., 2023)

CEA with Apc^GD1333, p53^GD4483

(Quintero and Bangi, 2023)

CEA with Apc^GD1333, Pten^RNAi.UAS.cUa, p53^GD4483

(Quintero and Bangi, 2023)

CEA with Apc^GD1333, Med^GD1483, p53^GD4483

(Quintero and Bangi, 2023)

model of high grade glioma

CEA with Pten^{RNAi.Exel.UAS}

(Gangwani et al., 2020)

CEA

(Liu et al., 2021)

model of brain cancer

CEA with dlg1^GD4689

(Manzanero-Ortiz et al., 2021)

CEA with l(2)gl^KK100777

(Manzanero-Ortiz et al., 2021)

CEA with wts^KK101055

(Manzanero-Ortiz et al., 2021)

CEA with scrib⁶⁷³

(Manzanero-Ortiz et al., 2021)

Ras85D^V152G.UASp

model of Noonan syndrome 3

CEA

(Cattaneo et al., 2020)

Ras85D^{G12V.UAS.Tag:FLAG,Tag:polyHis}

model of cancer

CEA

(Washington et al., 2020)

Ras85D^{Y4F.G12V.UAS.Tag:FLAG,Tag:polyHis}

model of cancer

CEA

(Washington et al., 2020)

Ras85D^V12.QUAS.cHa

model of cancer

CEA with scrib¹

(Hodgson et al., 2021)

Ras85D^V12.QUAS.cLa

model of cancer

CEA with scrib^{QUAS.HMS01490}

(Bakopoulos et al., 2023, Lodge et al., 2021)

Ras85D^G12D.UAS.cSa

model of pancreatic ductal adenocarcinoma

CEA with CycE^{UAS.Tag:HA.Medsh}, Med^{RNAi.UAS.CycE-HA}, p53^{RNAi.UAS.RasG12D}

(Sekiya et al., 2023)

Ras85D^{G12D.UAS.p53sh}

model of pancreatic ductal adenocarcinoma

CEA with CycE^{UAS.Tag:HA.Medsh}, Med^{RNAi.UAS.CycE-HA}, p53^{RNAi.UAS.RasG12D}

(Sekiya et al., 2023)

Modifiers Based on Experimental Evidence ( 19 )

Allele

Disease

Interaction

References

Ras85D^HMS01294

ameliorates hematologic cancer

modeled by mxc¹

(Kurihara et al., 2020)

Ras85D^ΔC40B

ameliorates multiple endocrine neoplasia type 2B

modeled by Ret^MEN2B.GMR

(Read et al., 2005)

Ras85D⁰⁶⁶⁷⁷

ameliorates autosomal dominant cerebellar ataxia

modeled by Hsap\ATXN1^82Q.UAS

(Park et al., 2013)

ameliorates multiple endocrine neoplasia type 2B

modeled by Ret^MEN2B.GMR

(Read et al., 2005)

ameliorates multiple endocrine neoplasia type 2A

modeled by Ret^MEN2A.GMR

(Read et al., 2005)

ameliorates alveolar rhabdomyosarcoma

modeled by Hsap\FOXO1::Hsap\PAX7^UAS.cGa

(Galindo et al., 2006)

Ras85D^G13Q.UAS

model of cancer

is exacerbated by ITP^UAS.F

(Xu et al., 2023)

Ras85D^N17.UAS

ameliorates brain glioma

modeled by btl::Egfr^λ.UAS, Pi3K92E^{UAS.Tag:MYC,Tag:PM(hKRAS)}

(Read et al., 2009)

Ras85D^Q13.UAS

model of cancer

is ameliorated by Cat^UAS.cAa

(Tamamouna et al., 2021)

is ameliorated by Sod1^UAS.cAa

(Tamamouna et al., 2021)

is ameliorated by btl^DN.UAS

(Tamamouna et al., 2021)

Ras85D^V12.GMR

model of cancer

is ameliorated by InR^GL00139

(Okada et al., 2023)

is ameliorated by InR^JF01183

(Okada et al., 2023)

is ameliorated by InR^JF01482

(Okada et al., 2023)

is ameliorated by NetB^VSH330183

(Okada et al., 2023)

is ameliorated by InR^K1409A.UAS

(Okada et al., 2023)

is ameliorated by NetB^Δ

(Okada et al., 2023)

is ameliorated by NetB^KK103672

(Okada et al., 2023)

is ameliorated by unc-5^HMS01099

(Okada et al., 2023)

is ameliorated by unc-5^KK102074

(Okada et al., 2023)

is ameliorated by unc-5^MI04273

(Okada et al., 2023)

Ras85D^V12.UAS

model of carcinoma

is exacerbated by mys^RNAi.UAS.cUa

(Martínez-Abarca Millán and Martín-Bermudo, 2023)

is exacerbated by mys^RNAi.UAS.cUa

(Martínez-Abarca Millán and Martín-Bermudo, 2023)

is ameliorated by Atg1^GD7149

(Pérez et al., 2015)

is ameliorated by HAdV-C\E4orf4^UAS.cPa

(Rosen et al., 2019)

is ameliorated by HAdV-C\E4orf4^UAS.cPb

(Rosen et al., 2019)

is exacerbated by dap^HMS01610

(Ito and Igaki, 2021)

is exacerbated by dap^HMS05362

(Ito and Igaki, 2021)

is ameliorated by pnt^P1.UAS

(Ito and Igaki, 2021)

is exacerbated by hep^Act.UAS

(Uhlirova and Bohmann, 2006)

is exacerbated by egr^UAS.cIa

(Igaki et al., 2006)

is exacerbated by ZnT86D^KK101698

(Wei et al., 2021)

is exacerbated by msn¹⁷²

(Kong et al., 2021)

is exacerbated by msn³²⁰⁸

(Kong et al., 2021)

is exacerbated by sna^UAS.cAa

(Wu et al., 2021)

is exacerbated by l(2)gl⁴

(Wu et al., 2021)

is ameliorated by rl^GD4697

(Murcia et al., 2019)

is ameliorated by Raf^DN.UAS

(Zoranovic et al., 2018)

is exacerbated by Tsp29Fb^GD1018

(Zoranovic et al., 2018)

is ameliorated by Tsp29Fb^UAS.Tag:HA

(Zoranovic et al., 2018)

is ameliorated by Hsap\CDKN1A^UAS.cHa

(Karim and Rubin, 1998)

is ameliorated by Raf^XS-2541

(Karim and Rubin, 1998)

is exacerbated by rl^Sem

(Karim and Rubin, 1998)

is exacerbated by Egfrap^ΔSH2

(Soler Beatty et al., 2021)

is exacerbated by Egfrap^HMJ23378

(Soler Beatty et al., 2021)

is exacerbated by Egfrap^LS

(Soler Beatty et al., 2021)

is exacerbated by Egfrap^L

(Soler Beatty et al., 2021)

is exacerbated by PVRAP^HMJ23233

(Soler Beatty et al., 2021)

model of cancer

is ameliorated by Sec15^KK101708

(Chabu and Xu, 2014)

is ameliorated by Sec8^KK101531

(Chabu and Xu, 2014)

is ameliorated by Sec6^GD11616

(Chabu and Xu, 2014)

is ameliorated by Sec15¹

(Chabu and Xu, 2014)

is ameliorated by Sec15^GD12109

(Chabu and Xu, 2014)

is ameliorated by Src64B^GD12263

(Ma et al., 2013)

is ameliorated by Dronc^NIG.8091R

(Waghmare et al., 2024)

is ameliorated by bsk^DN.UAS

(Waghmare et al., 2024)

is ameliorated by sgg^S9A.UAS

(Waghmare et al., 2024)

is ameliorated by yki^RNAi.N.UAS

(Waghmare et al., 2024)

is ameliorated by yki^RNAi.C.UAS

(Waghmare et al., 2024)

is ameliorated by chinmo¹

(Enomoto et al., 2021)

is exacerbated by PVRAP¹

(Martínez-Abarca Millán et al., 2023)

is exacerbated by PVRAP^HMJ23233

(Martínez-Abarca Millán et al., 2023)

is exacerbated by by^33c

(Martínez-Abarca Millán et al., 2023)

is exacerbated by by^VSH330366

(Martínez-Abarca Millán et al., 2023)

is exacerbated by Csk^Q156Stop

(Hirabayashi et al., 2013)

is exacerbated by emei¹

(Ma et al., 2020)

is exacerbated by emei²

(Ma et al., 2020)

is exacerbated by emei³

(Ma et al., 2020)

is ameliorated by Arc1^esm18

(Khalili et al., 2023)

is exacerbated by Nek2^UAS.GFP

(Das et al., 2013)

model of intestinal cancer

is ameliorated by Cortactin^HMS00658

(Cabrera et al., 2023)

is ameliorated by Cortactin^KK108594

(Cabrera et al., 2023)

is ameliorated by shg^HMS00693

(Cabrera et al., 2023)

is ameliorated by shg^JF02769

(Cabrera et al., 2023)

exacerbates alveolar rhabdomyosarcoma

modeled by Hsap\FOXO1::Hsap\PAX7^UAS.cGa

(Galindo et al., 2006)

exacerbates gastrointestinal system cancer

modeled by Apc2^g10, Apc^Q8

(Wang et al., 2013)

model of colorectal cancer

is ameliorated by Timp^UAS.cPa

(Bangi et al., 2012)

is ameliorated by Jra^NIG.2275R

(Bangi et al., 2012)

is ameliorated by bsk^DN.UAS

(Bangi et al., 2012)

is ameliorated by bsk^HMS00777

(Bangi et al., 2012)

is exacerbated by hep^Act.UAS

(Bangi et al., 2012)

is exacerbated by imd^UAS.cGa

(Bangi et al., 2012)

ameliorates cancer

modeled by dlg1^A40.2

(Parisi et al., 2014)

exacerbates carcinoma

modeled by scrib¹

(Brumby and Richardson, 2003)

modeled by arm^UAS.Exel

(Zhang et al., 2019)

model of prostate cancer

is ameliorated by Egfr^GD1654

(Rambur et al., 2020)

is ameliorated by Pi3K92E^HMC05152

(Rambur et al., 2020)

is ameliorated by mTor^GL00156

(Rambur et al., 2020)

is ameliorated by rl^HMS00173

(Rambur et al., 2020)

is ameliorated by spi^HMS01120

(Rambur et al., 2020)

exacerbates intestinal cancer

modeled by Rab11^KK108297

(Nie et al., 2019)

exacerbates cancer

modeled by Hipk^UAS.Tag:HA

(Blaquiere et al., 2018)

model of kidney cancer

is ameliorated by Pka-C1^B3

(Zeng et al., 2010)

is ameliorated by mTor^ΔP

(Zeng et al., 2010)

exacerbates Alzheimer's disease 1

modeled by Hsap\APP^{Aβ42.UAS.cUa}

(Cheng et al., 2021)

exacerbates hematologic cancer

modeled by mxc¹

(Kurihara et al., 2020)

Ras85D^V12.ey

model of carcinoma

is ameliorated by Raf^XS-2541

(Karim and Rubin, 1998)

Ras85D^e1B

ameliorates alveolar rhabdomyosarcoma

modeled by Hsap\FOXO1::Hsap\PAX7^UAS.cGa

(Galindo et al., 2006)

exacerbates viral infectious disease

modeled by EBV\BZLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

exacerbates infectious mononucleosis

modeled by EBV\BZLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

exacerbates Epstein-Barr virus hepatitis

modeled by EBV\BZLF1^GMR.PA

(Adamson and Lajeunesse, 2012)

ameliorates gastrointestinal system cancer

modeled by Apc2^g10, Apc^Q8

(Wang et al., 2013)

exacerbates tuberous sclerosis

modeled by Tsc1^UAS.cTa, gig^UAS.cTa

(Tapon et al., 2001)

ameliorates cancer

modeled by Alk^UAS.cLa

(Wolfstetter et al., 2020)

Ras85D^e2F

ameliorates alveolar rhabdomyosarcoma

modeled by Hsap\FOXO1::Hsap\PAX7^UAS.cGa

(Galindo et al., 2006)

Ras85D^unspecified

ameliorates neurofibromatosis

modeled by Nf1^E2

(Walker et al., 2006)

Ras85D^V12.cUa.UAS

model of cancer

is exacerbated by Ptp61F^Δ

(Liu et al., 2022)

is exacerbated by ex^e1

(Liu et al., 2022)

is exacerbated by Not3^KK102144

(Vicente et al., 2018)

is exacerbated by M6^W186stop

(Dunn et al., 2018)

is ameliorated by Ptip³⁸⁰⁴

(Dong et al., 2021)

is exacerbated by p53^UAS.cUa

(Dong et al., 2021)

is ameliorated by Ilp8^MI00727

(Yeom et al., 2021)

model of intestinal cancer

is ameliorated by Cortactin^HMS00658

(Kim et al., 2022)

is exacerbated by Clbn^1Q

(Dai et al., 2020)

model of high grade glioma

is ameliorated by Dcp-1^RNAi.UAS.cUa

(Liu et al., 2021)

is exacerbated by Nmnat^UAS.PC

(Liu et al., 2021)

is ameliorated by Nmnat^RNAi.UAS.cUa

(Liu et al., 2021)

exacerbates carcinoma

modeled by Nkap^GD11807

(Guo et al., 2024)

model of carcinoma

is exacerbated by Nkap^GD11807

(Guo et al., 2024)

Ras85D^GD12553

ameliorates colorectal cancer

modeled by Src42A^CA.UAS

(Cordero et al., 2014)

modeled by Src64B^UAS.cCa

(Cordero et al., 2014)

ameliorates neurofibromatosis

modeled by Nf1^JF01866

(Georganta et al., 2021)

Ras85D^KK108029

ameliorates colorectal cancer

modeled by Src42A^CA.UAS

(Cordero et al., 2014)

modeled by Src64B^UAS.cCa

(Cordero et al., 2014)

ameliorates intestinal cancer

modeled by Egfr^UAS.cBa

(Nászai et al., 2021)

Ras85D^JF02478

ameliorates colorectal cancer

modeled by SH3PX1^HMJ21552

(Zhang et al., 2019)

Ras85D^{G12V.UAS.Tag:FLAG,Tag:polyHis}

model of cancer

is exacerbated by Egfr^2.UAS

(Washington et al., 2020)

is ameliorated by Rabex-5^{DPYT.UAS.Tag:MYC}

(Washington et al., 2020)

is exacerbated by hop^JF01267

(Washington et al., 2020)

Ras85D^{Y4F.G12V.UAS.Tag:FLAG,Tag:polyHis}

model of cancer

is exacerbated by Egfr^2.UAS

(Washington et al., 2020)

is ameliorated by Rabex-5^{DPYT.UAS.Tag:MYC}

(Washington et al., 2020)

Ras85D^DN.UAS.cUa

ameliorates Alzheimer's disease 1

modeled by Hsap\APP^{Aβ42.UAS.cUa}

(Cheng et al., 2021)

Models Based on Experimental Evidence ( 13 )

Allele

Disease

Evidence

References

N^DN.UAS.cUa

model of cancer

CEA with Ras85D^V12.cUa.UAS

(Lee et al., 2021)

CEA

(Lee et al., 2021, Tamamouna et al., 2021)

CEA with Ras85D^V12.UAS

(Xu et al., 2023)

model of intestinal cancer

CEA

(Singh et al., 2016)

N^ICN.UAS

model of cancer

CEA

(Wang et al., 2021, Harsh and Eleftherianos, 2020)

CEA with Mef2^UAS.cUa

(Harsh and Eleftherianos, 2020)

model of carcinoma

CEA with Mef2^UAS.cUa

(Pallavi et al., 2012)

CEA with egr^UAS.cUa

(Pallavi et al., 2012)

model of brain cancer

CEA

(Wang et al., 2006)

N^UAS.cMa

model of adenoid cystic carcinoma

CEA with Hsap\MYB^ΔC.UAS, Xpd^{RNAi.UAS.012.1}, ft^{RNAi.UAS.012.1}, kug^{RNAi.UAS.012.1}

(Bangi et al., 2021)

CEA with Hsap\MYB^ΔC.UAS, Xpd^{RNAi.UAS.012.2}, ft^{RNAi.UAS.012.2}, kug^{RNAi.UAS.012.2}

(Bangi et al., 2021)

N^UAS.icd

model of central nervous system cancer

CEA

(Zacharioudaki et al., 2016)

N^RNAi.P.UAS

model of intestinal cancer

CEA

(Chen et al., 2021)

CEA with mys^GD15002

(Chen et al., 2021)

model of cancer

CEA with Ras85D^V12.UAS

(Tamamouna et al., 2021)

N^intra.GS.UAS

model of neurodegenerative disease

CEA

(Loewen et al., 2018)

N^{UAS.Tag:V5,Tag:polyHis}

model of brain cancer

CEA

(Ojha et al., 2022)

model of cancer

CEA

(Khaket et al., 2024)

N^GD144

model of alcohol use disorder

CEA

(Petruccelli et al., 2018)

N^GD14477

model of intestinal cancer

CEA

(Banreti et al., 2022)

model of colorectal cancer

CEA

(Zipper et al., 2022)

model of cancer

CEA

(Brás et al., 2021)

N^HD_CFD01184

model of intestinal cancer

CEC with Spyo\Cas9^UAS.uM.-FRT

(Bahuguna et al., 2021)

CEC with Spyo\Cas9^UAS.P2

(Bahuguna et al., 2021)

N^CA.UAS.cUa

model of central nervous system cancer

CEA

(Magadi et al., 2020, Zacharioudaki et al., 2016)

model of carcinoma

CEA with l(2)gl^GD4047

(Jevitt et al., 2021)

model of adenocarcinoma

CEA

(Casas-Tintó et al., 2016)

CEA with wupA^f06492

(Casas-Tintó et al., 2016)

model of cervical cancer

CEA with Hsap\UBE3A^UAS.cRa, HPV18\E6^UAS.Tag:MYC

(Padash Barmchi et al., 2016)

N^RNAi.UAS.cUa

model of intestinal cancer

CEA

(Ayyaz et al., 2015)

N^ΔE.UAS

model of central nervous system cancer

CEA

(Voutyraki et al., 2023, Voutyraki et al., 2022)

Modifiers Based on Experimental Evidence ( 22 )

Allele

Disease

Interaction

References

N^DN.UAS.cUa

model of cancer

is ameliorated by wg^JF01257

(Lee et al., 2021)

is ameliorated by Atg1^UAS.cSa

(Lee et al., 2021)

ameliorates carcinoma

modeled by Vps25^N55

(Herz et al., 2006)

modeled by ph-d⁵⁰⁵, ph-p⁵⁰⁵

(Beira et al., 2018)

ameliorates intestinal cancer

modeled by yki^{S111A.S168A.S250A.UAS.Tag:V5}

(Pranoto et al., 2023)

N^ECN.UAS

ameliorates cancer

modeled by Src64B^UAS.cCa

(Enomoto et al., 2021)

N^{FLN.ΔCdc10.UAS}

ameliorates C9orf72 frontotemporal dementia and/or amyotrophic lateral sclerosis

modeled by Zzzz\poly-GR^{80.UAS.Tag:FLAG}

(Li et al., 2020)

N^ICN.UAS

model of cancer

is ameliorated by CycE^HMS00060

(Wang et al., 2021)

is ameliorated by Dref^JF02232

(Wang et al., 2021)

is ameliorated by RPA1^GL00350

(Wang et al., 2021)

is ameliorated by SMC5^HMC04343

(Wang et al., 2021)

is ameliorated by fzr^GD9960

(Wang et al., 2021)

is ameliorated by mei-41^GL00284

(Wang et al., 2021)

is ameliorated by mre11^HMC02995

(Wang et al., 2021)

is exacerbated by stg^UAS.Tag:HA

(Wang et al., 2021)

is ameliorated by stg^RNAi.UAS.cUa

(Wang et al., 2021)

exacerbates cancer

modeled by Src64B^UAS.cCa

(Enomoto et al., 2021)

modeled by Hipk^UAS.Tag:HA

(Blaquiere et al., 2018)

exacerbates carcinoma

modeled by scrib¹

(Brumby and Richardson, 2003)

N^UAS.icd

model of central nervous system cancer

is ameliorated by hth^C1

(Zacharioudaki et al., 2016)

is exacerbated by mira^HMS00347

(Zacharioudaki et al., 2016)

is ameliorated by svp¹

(Zacharioudaki et al., 2016)

is ameliorated by hth^B2

(Zacharioudaki et al., 2016)

N^RNAi.P.UAS

model of intestinal cancer

is exacerbated by Cat^HMS00990

(Chen et al., 2021)

is ameliorated by Cat^UAS.cUa

(Chen et al., 2021)

is ameliorated by Sod2^UAS.cMa

(Chen et al., 2021)

is exacerbated by cnc^HMS00650

(Chen et al., 2021)

is exacerbated by Sod2^HMS00499

(Chen et al., 2021)

is ameliorated by cnc^UAS.cSa

(Chen et al., 2021)

ameliorates carcinoma

modeled by Vps25^A3

(Vaccari and Bilder, 2005)

N^fa-swb

ameliorates Parkinson's disease 1

modeled by Hsap\SNCA^UAS.cJa

(Rousseaux et al., 2018)

N^intra.GS.UAS

ameliorates cancer

modeled by Pvr^{λ.UASp.Tag:MYC}

(Wang et al., 2023)

exacerbates carcinoma

modeled by Nkap^GD11807

(Guo et al., 2024)

N^l1N-ts1

ameliorates brain cancer

modeled by aurA⁸⁸³⁹

(Wang et al., 2006)

ameliorates frontotemporal dementia and/or amyotrophic lateral sclerosis 7

modeled by Hsap\CHMP2B^Intron5.UAS

(Wilson et al., 2020)

N^nd-1

ameliorates Schimke immuno-osseous dysplasia

modeled by Marcal1^UAS.cBa

(Morimoto et al., 2016)

N^nd-3

ameliorates Schimke immuno-osseous dysplasia

modeled by Marcal1^UAS.cBa

(Morimoto et al., 2016)

N^{UAS.Tag:V5,Tag:polyHis}

model of brain cancer

is ameliorated by ND-49^HM05059

(Ojha et al., 2022)

is ameliorated by Scer\NDI1^UAS.cBa

(Ojha et al., 2022)

ameliorates C9orf72 frontotemporal dementia and/or amyotrophic lateral sclerosis

modeled by Zzzz\poly-GR^{80.UAS.Tag:FLAG}

(Li et al., 2020)

modeled by Zzzz\poly-GA^{80.UAS.Tag:FLAG}

(Li et al., 2020)

modeled by Zzzz\poly-PR^{80.UAS.Tag:FLAG}

(Li et al., 2020)

model of cancer

is ameliorated by TER94^JF03402

(Khaket et al., 2024)

is ameliorated by pelo^KK101657

(Khaket et al., 2024)

is ameliorated by pelo^{UAS.ORF.GW.Tag:HA}

(Khaket et al., 2024)

is ameliorated by pix^JF01190

(Khaket et al., 2024)

is ameliorated by pix^{UAS.ORF.Tag:HA}

(Khaket et al., 2024)

is ameliorated by CG11414^HMJ23120

(Khaket et al., 2024)

is ameliorated by Cnot4^JF03203

(Khaket et al., 2024)

is ameliorated by SARS-CoV-2\nsp1^UAS.cZa

(Khaket et al., 2024)

N^JF01637

ameliorates carcinoma

modeled by l(2)gl^GD4047

(Chatterjee et al., 2023)

modeled by Nkap^GD11807

(Guo et al., 2024)

N^GD14477

model of intestinal cancer

is exacerbated by Pcmt^GD8637

(Banreti et al., 2022)

is exacerbated by Pcmt^RNAi.UAS

(Banreti et al., 2022)

ameliorates cancer

modeled by Src64B^UAS.cCa

(Enomoto et al., 2021)

model of colorectal cancer

is ameliorated by mir-277^UAS.cSa

(Zipper et al., 2022)

ameliorates brain cancer

modeled by Vps35^E42

(Li et al., 2018)

exacerbates cancer

modeled by Mps1^GL00184

(Brás et al., 2021)

modeled by Mps1^HMS01546

(Brás et al., 2021)

modeled by mad2^GLC01381

(Brás et al., 2021)

model of cancer

is exacerbated by Mps1^GL00184

(Brás et al., 2021)

is exacerbated by Mps1^HMS01546

(Brás et al., 2021)

is exacerbated by mad2^GLC01381

(Brás et al., 2021)

N^NICD.UASp

exacerbates carcinoma

modeled by l(2)gl^GD4047

(Chatterjee et al., 2023)

N^{sfGFP,Tag:FLAG}

ameliorates Adams-Oliver syndrome

modeled by Su(H)^T4

(Gagliani et al., 2022)

N^JF02959

ameliorates rhabdoid cancer

modeled by Snr1^HMS00363, BacA\p35^UAS.cHa

(Xie et al., 2017)

N^RNAi.lexAop

ameliorates carcinoma

modeled by Egfr^UAS.cBa, psq^KK111691

(Boukhatmi et al., 2020)

N^UAS.cGa

ameliorates autism spectrum disorder

modeled by Nrx-IV⁴³⁰⁴

(Grice et al., 2015)

N^CA.UAS.cUa

model of central nervous system cancer

is ameliorated by zfh1^UAS.cPa

(Magadi et al., 2020)

is ameliorated by gcm^{UAS.ORF.GW.Tag:HA}

(Magadi et al., 2020)

exacerbates carcinoma

modeled by l(2)gl^GD4047

(Jevitt et al., 2021)

N^RNAi.UAS.cUa

model of intestinal cancer

is ameliorated by Smox^JF02320

(Ayyaz et al., 2015)

N^ΔE.UAS

model of central nervous system cancer

is exacerbated by InR^A1325D.UAS

(Voutyraki et al., 2023)

is ameliorated by InR^K1409A.UAS

(Voutyraki et al., 2023)

is ameliorated by Imp^HMS01168

(Voutyraki et al., 2023)

Hsap\UBE3A

Models Based on Experimental Evidence ( 2 )

Allele

Disease

Evidence

References

Hsap\UBE3A^UAS.cRa

DOES NOT model cervical cancer

CEA with HPV18\E6^UAS.Tag:MYC

(Padash Barmchi et al., 2016)

model of cervical cancer

CEA with HPV18\E6^UAS.Tag:MYC, InR^DN.UAS.cUa

(Padash Barmchi et al., 2016)

CEA with HPV18\E6^UAS.Tag:MYC, Ras85D^V12.cUa.UAS

(Padash Barmchi et al., 2016)

CEA with HPV18\E6^{V158A.UAS.Tag:MYC}, Ras85D^V12.cUa.UAS

(Padash Barmchi et al., 2016)

CEA with HPV18\E6^UAS.Tag:MYC, N^CA.UAS.cUa

(Padash Barmchi et al., 2016)

model of carcinoma

CEA with HPV16\E5^UAS.Tag:HA

(Hashemi et al., 2022)

CEA with HPV16\E6^UAS.cHa

(Hashemi et al., 2022)

CEA with HPV16\E7^UAS.cHa

(Hashemi et al., 2022)

CEA with HPV18\E6^UAS.Tag:MYC

(Padash Barmchi et al., 2021)

CEA with HPV18\E6^UAS.Tag:MYC, Ras64B^Val14.UAS

(Padash Barmchi et al., 2021)

model of cancer

CEA

(Collins et al., 2023)

CEA with HPV18\E6^UAS.Tag:MYC

(Collins et al., 2023)

model of epilepsy

CEA

(Hope et al., 2017)

model of Human papillomavirus infectious disease

CEA with HPV18\E6^UAS.Tag:MYC

(Padash Barmchi et al., 2021)

Hsap\UBE3A^UAS.iso1.cCa

model of intellectual disability

CEA

(Chakraborty et al., 2015)

Modifiers Based on Experimental Evidence ( 1 )

Allele

Disease

Interaction

References

Hsap\UBE3A^UAS.iso1.cCa

ameliorates intellectual disability

modeled by Ube3a^unspecified

(Chakraborty et al., 2015)

HPV18\E6

Models Based on Experimental Evidence ( 2 )

Allele

Disease

Evidence

References

HPV18\E6^UAS.Tag:MYC

DOES NOT model cervical cancer

CEA with Hsap\UBE3A^UAS.cRa

(Padash Barmchi et al., 2016)

model of cervical cancer

CEA with Hsap\UBE3A^UAS.cRa, InR^DN.UAS.cUa

(Padash Barmchi et al., 2016)

CEA with Hsap\UBE3A^UAS.cRa, Ras85D^V12.cUa.UAS

(Padash Barmchi et al., 2016)

CEA with Hsap\UBE3A^UAS.cRa, N^CA.UAS.cUa

(Padash Barmchi et al., 2016)

model of cancer

CEA

(Collins et al., 2023)

CEA with Hsap\UBE3A^UAS.cRa

(Collins et al., 2023)

model of Human papillomavirus infectious disease

CEA with Hsap\UBE3A^UAS.cRa

(Padash Barmchi et al., 2021)

model of carcinoma

CEA with Hsap\UBE3A^UAS.cRa

(Padash Barmchi et al., 2021)

CEA with Hsap\UBE3A^UAS.cRa, Ras64B^Val14.UAS

(Padash Barmchi et al., 2021)

HPV18\E6^{V158A.UAS.Tag:MYC}

model of cervical cancer

CEA with Hsap\UBE3A^UAS.cRa, Ras85D^V12.cUa.UAS

(Padash Barmchi et al., 2016)

Modifiers Based on Experimental Evidence ( 0 )

Allele

Disease

Interaction

References

HPV16\E5

Models Based on Experimental Evidence ( 1 )

Allele

Disease

Evidence

References

HPV16\E5^UAS.Tag:HA

model of carcinoma

CEA with Hsap\UBE3A^UAS.cRa

(Hashemi et al., 2022)

Modifiers Based on Experimental Evidence ( 0 )

Allele

Disease

Interaction

References

Alleles Representing Disease-Implicated Variants

Genetic Tools, Stocks and Reagents

Sources of Stocks

Contact lab of origin for a reagent not available from a public stock center.

Bloomington Stock Center Disease Page

Related mammalian, viral, bacterial, or synthetic transgenes

Allele

Transgene

Publicly Available Stocks

Hsap\UBE3A^UAS.cRa

P{UAS-hUBE3A.R}

w^*; P{UAS-hUBE3A.R}31/CyO

Hsap\UBE3A^{UAS.iso1.Tag:MYC}

P{UAS-UBE3A.iso1.3myc}

Hsap\UBE3A^UAS.iso1.cCa

P{UAS-UBE3A.iso1.C}

HPV18\E6^UAS.Tag:MYC

P{UAS-HPV18E6.MYC}

HPV18\E6^{V158A.UAS.Tag:MYC}

P{UAS-HPV18E6.V158A.MYC}

HPV16\E5^UAS.Tag:HA

P{UAS-HPV16-E5-E6-E7}

Selected Drosophila transgenes

Allele

Transgene

Publicly Available Stocks

N^HD_CFD01184

P{HD_CFD01184}

P{hsFLP}1, y¹ w¹¹¹⁸; P{HD_CFD01184}attP40/CyO-GFP

y¹ w^*; P{UAS-Delta.ΔE}B2a2

N^ECN.UAS

P{UAS-N.ECN}

P{hsFLP}12, y¹ w^*; P{UAS-N.ECN}2; MKRS/TM2

N^ICN.UAS

P{UAS-N.ICN}

N^{FLN.ΔCdc10.UAS}

P{UAS-N.FLNDeltaCdc10}

N^{UAS.Tag:V5,Tag:polyHis}

P{UAS-N.V5}

N^{sfGFP,Tag:FLAG}

PBac{N-GFP.FLAG}

y¹ w^*; PBac{N-GFP.FLAG}VK00033/TM6C, Sb¹

Ras85D^{G12V.UAS.Tag:FLAG,Tag:polyHis}

P{UAS-FH-Ras85D.G12V}

Ras85D^{Y4F.G12V.UAS.Tag:FLAG,Tag:polyHis}

P{UAS-FH-Ras85D.Y4F.G12V}

Ras85D^V12.QUAS.cHa

P{QUAS-Ras85D.V12.H}

Ras85D^V12.QUAS.cLa

PBac{QUAS-Ras85D.V12.L}

Ras85D^{G12D.UAS.p53sh}

P{UAS-Ras85D(G12D).UAS-p53(shRNA)}

Ras85D^V12.UAS

P{UAS-Ras85D.V12}

w¹¹¹⁸; P{UAS-Ras85D.V12}TL1

Ras85D^N17.UAS

P{UAS-Ras85D.N17}

P{UAS-Ras85D.N17}TL1, w¹¹¹⁸

P{UAS-Ras85D.V12.S35}

RNAi constructs available

Allele

Transgene

Publicly Available Stocks

N^RNAi.lexAop

P{lexAop-N.RNAi}

N^{RNAi.13xlexAop.cZa}

P{13xlexAop-N.RNAi.Z}

w^*; P{UAS-N.RNAi.P}9G

w¹¹¹⁸; P{GD14477}v27228/TM3

y¹ v¹; P{TRiP.JF02959}attP2

N^JF01637

P{TRiP.JF01637}

y¹ v¹; P{TRiP.JF01637}attP2

N^JF01043

P{TRiP.JF01043}

y¹ v¹; P{TRiP.JF01043}attP2

N^JF01053

P{TRiP.JF01053}

y¹ v¹; P{TRiP.JF01053}attP2

N^JF01356

P{TRiP.JF01356}

y¹ v¹; P{TRiP.JF01356}attP2

N^JF01693

P{TRiP.JF01693}

y¹ v¹; P{TRiP.JF01693}attP2

y¹ v¹; P{TRiP.HMS00001}attP2

N^HMS00009

P{TRiP.HMS00009}

y¹ v¹; P{TRiP.HMS00009}attP2

y¹ sc^* v¹ sev²¹; P{TRiP.GL00092}attP2

N^GLV21004

P{TRiP.GLV21004}

y¹ sc^* v¹ sev²¹; P{TRiP.GLV21004}attP2

Ras85D^{TH201501177.S}

w¹¹¹⁸; P{GD12553}v28129

y¹ v¹; P{TRiP.JF02478}attP2

y¹ sc^* v¹ sev²¹; P{TRiP.HMS01294}attP2

Ras85D^GL00336

P{TRiP.GL00336}

y¹ sc^* v¹ sev²¹; P{TRiP.GL00336}attP2/TM3, Sb¹

Selected Drosophila classical alleles

Allele

Allele class

Mutagen

Publicly Available Stocks

N^ETX52

amorphic allele - genetic evidence

Delta2-3 transposase

N^55e11

loss of function allele

spontaneous

N^55e11 P{neoFRT}19A/FM7c

N^fa-g

loss of function allele

spontaneous

w^a N^fa-g; Rho1^E3.10/CyO

N^264-40

amorphic allele - genetic evidence

X ray

w^a N^264-40 rb¹/C(1)DX, y¹ f¹; Dp(1;2)72c21/+

N^FE1

loss of function allele

X ray

N^l1N-ts1

ethyl methanesulfonate

y¹ N^l1N-ts1 g² f¹/C(1)DX, y¹ w¹ f¹

N^S-317

loss of function allele

ethyl methanesulfonate

N^l1N-2

amorphic allele - genetic evidence

gamma ray

N^FX9

loss of function allele

X ray

N^FE2

loss of function allele

X ray

N^FX8

loss of function allele

X ray

N¹

loss of function allele

y¹ w^* N¹/FM7c, P{GAL4-twi.G}108.4, P{UAS-2xEGFP}AX

N^FX4

loss of function allele

X ray

N^eU10

loss of function allele

ethyl methanesulfonate

N^eAS7b

loss of function allele

ethyl methanesulfonate

N^60g11

amorphic allele - genetic evidence

X ray

N^FX2

loss of function allele

X ray

N^XL86

loss of function allele

ethyl methanesulfonate

N²

loss of function allele

N^FX5

loss of function allele

X ray

N^FX7

loss of function allele

X ray

N^Yi66

loss of function allele

ethyl methanesulfonate

N^264-47

loss of function allele

X ray

N^264-39

loss of function allele

X ray

w^ch2 N^264-39/FM4, Bar⁺

N^X81K1

loss of function allele

N^fa-swb

X ray

w^a N^fa-swb

N³

loss of function allele

N^3b22

loss of function allele

ethyl methanesulfonate

N^FX6

loss of function allele

X ray

N^XK11

amorphic allele - genetic evidence

N^nd-1

loss of function allele

spontaneous

N^nd-1 rb¹

N^M1

loss of function allele

ethyl methanesulfonate

N^FX3

loss of function allele

X ray

N^FX1

loss of function allele

X ray

N^X114

loss of function allele

ethyl methanesulfonate

N^66l2

amorphic allele - genetic evidence

N^nd-3

X ray

N^nd-3 rb¹/C(1)DX, y¹ f¹

Ras85D⁰⁶⁶⁷⁷

P-element activity

P{PZ}Ras85D⁰⁶⁶⁷⁷ ry⁵⁰⁶/TM3, ry^RK Sb¹ Ser¹

Ras85D^e2F

sev¹⁴; Ras85D^e2F/TM3, Sb¹

Ras85D^e1B

ethyl methanesulfonate

sev¹⁴; Ras85D^e1B/TM3, Sb¹

Ras85D^unspecified

Ras85D^ΔC40B

loss of function allele

Ras85D^x7b

loss of function allele

P-element activity

Ras85D^Δ17b

amorphic allele - genetic evidence

References (7)

Report Sections

Open Close